Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin

International Journal of Pharmaceutics

Volumn 434, Issue 1-2, 2012, Pages 209-214

  Li, Ying ^a   Zheng, Xuemin ^b   Cao, Zhenghong ^c   Xu, Weiren ^b   Zhang, Jianning ^a   Gong, Min ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Blood residence time; Cell penetrating peptide; Doxorubicin; Self assembled peptide

Indexed keywords

CADY 1; DOXORUBICIN; DRUG CARRIER; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL MEMBRANE; CELL-PENETRATING PEPTIDES; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HELA CELLS; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED DBA; MICE, INBRED ICR; PEPTIDES; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864115176     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.06.003     Document Type: Article

References (26)

1. E.V. Batrakova Overcoming multidrug resistance using silica nanoparticles PEG-b-PLA polymeric micelles loaded with doxorubicin Nanomedicine (Lond.) 6 2011 1492 1493
2. S.K. Carter Adriamycin - a review J. Natl. Cancer Inst. 55 1975 1265 1274
3. L. Crombez, G. Aldrian-Herrada, K. Konate, Q.N. Nguyen, G.K. McMaster, R. Brasseur, F. Heitz, and G. Divita A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells Mol. Ther. 17 2009 95 103
4. L. Crombez, M.C. Morris, S. Deshayes, F. Heitz, and G. Divita Peptide-based nanoparticle for ex vivo and in vivo drug delivery Curr. Pharm. Des. 14 2008 3656 3665
5. J. Cui, C. Li, W. Guo, Y. Li, C. Wang, L. Zhang, Y. Hao, and Y. Wang Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J. Control. Release 118 2007 204 215
6. J. Fernandez-Carneado, M.J. Kogan, S. Pujals, and E. Giralt Amphipathic peptides and drug delivery Biopolymers 76 2004 196 203
7. A. Gabizon, D. Goren, Z. Fuks, Y. Barenholz, A. Dagan, and A. Meshorer Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers Cancer Res. 43 1983 4730 4735
8. A.A. Gabizon, H. Shmeeda, and S. Zalipsky Pros and cons of the liposome platform in cancer drug targeting J. Liposome Res. 16 2006 175 183
9. S. Galdiero, M. Vitiello, A. Falanga, M. Cantisani, N. Incoronato, and M. Galdiero Intracellular delivery: exploiting viral membranotropic peptides Curr. Drug Metab. 13 2012 93 104
10. M. Gou, H. Shi, G. Guo, K. Men, J. Zhang, L. Zheng, Z. Li, F. Luo, Z. Qian, X. Zhao, and Y. Wei Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micelles Nanotechnology 22 2011 095102
11. M. Gou, L. Zheng, X. Peng, K. Men, X. Zheng, S. Zeng, G. Guo, F. Luo, X. Zhao, L. Chen, Y. Wei, and Z. Qian Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro Int. J. Pharm. 375 2009 170 176
12. M. Hanada, S. Mizuno, A. Fukushima, Y. Saito, T. Noguchi, and T. Yamaoka A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex Jpn. J. Cancer Res. 89 1998 1229 1238
13. E.H. Herman, A. Rahman, V.J. Ferrans, J.A. Vick, and P.S. Schein Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation Cancer Res. 43 1983 5427 5432
14. F. Hudecz, Z. Banoczi, and G. Csik Medium-sized peptides as built in carriers for biologically active compounds Med. Res. Rev. 25 2005 679 736
15. P.M. Kanter, G.A. Bullard, F.G. Pilkiewicz, L.D. Mayer, P.R. Cullis, and Z.P. Pavelic Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs In Vivo 7 1993 85 95
16. K. Konate, L. Crombez, S. Deshayes, M. Decaffmeyer, A. Thomas, R. Brasseur, G. Aldrian, F. Heitz, and G. Divita Insight into the cellular uptake mechanism of a secondary amphipathic cell-penetrating peptide for siRNA delivery Biochemistry 49 2010 3393 3402
17. L.D. Mayer, L.C. Tai, M.B. Bally, G.N. Mitilenes, R.S. Ginsberg, and P.R. Cullis Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients Biochim. Biophys. Acta 1025 1990 143 151
18. P.J. Oliveira, J.A. Bjork, M.S. Santos, R.L. Leino, M.K. Froberg, A.J. Moreno, and K.B. Wallace Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity Toxicol. Appl. Pharmacol. 200 2004 159 168
19. L. Prongidi-Fix, M. Sugawara, P. Bertani, J. Raya, C. Leborgne, A. Kichler, and B. Bechinger Self-promoted cellular uptake of peptide/DNA transfection complexes Biochemistry 46 2007 11253 11262
20. M. Reches, and E. Gazit Controlled patterning of aligned self-assembled peptide nanotubes Nat. Nanotechnol. 1 2006 195 200
21. M.S. Sachdeva Drug targeting systems for cancer chemotherapy Expert Opin. Investig. Drugs 7 1998 1849 1864
22. P. Spallarossa, S. Garibaldi, P. Altieri, P. Fabbi, V. Manca, S. Nasti, P. Rossettin, G. Ghigliotti, A. Ballestrero, F. Patrone, A. Barsotti, and C. Brunelli Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro J. Mol. Cell. Cardiol. 37 2004 837 846
23. K. Wang, H.Q. Dong, H.Y. Wen, M. Xu, C. Li, Y.Y. Li, H.N. Jones, D.L. Shi, and X.Z. Zhang Novel vesicles self-assembled from amphiphilic star-armed PEG/polypeptide hybrid copolymers for drug delivery Macromol. Biosci. 11 2011 65 71
24. X. Yi, R. Bekeredjian, N.J. DeFilippis, Z. Siddiquee, E. Fernandez, and R.V. Shohet Transcriptional analysis of doxorubicin-induced cardiotoxicity Am. J. Physiol. Heart Circ. Physiol. 290 2006 H1098 H1102
25. X. Zheng, Y. Li, G. Fu, and M. Gong Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo Peptides 32 2011 964 970
26. X. Zheng, Y. Li, X. Li, L. Tang, W. Xu, and M. Gong Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes Diabetes Res. Clin. Pract. 93 2011 410 420